CORRESP 2 filename2.htm Converted by EDGARwiz

MEDITECH PHARMACEUTICALS INC.


PRO-FORMA CONSOLIDATED BALANCE SHEET (UNAUDITED)


MARCH 31, 2005



  

 BVI

 Bazhou

 Private

 Consolidating

 Pro-forma

Assets

 Meditech

 Deli Solar

 Deli Solar

 Placement

 Entries

 Consolidated

 Current assets

      

 Cash and cash equivalents

 $               -   

 $    200,442

 $    893,552

 $   5,184,630

$                   -

 $   6,278,624

 Trade accounts receivable

                    -   

                  -   

        255,049

  

          255,049

 Allowances for doubtful accounts

                    -   

                  -   

         (88,600)

                      -

                      -

           (88,600)

 Net trade accounts receivable

                    -   

                  -   

        166,449

                      -

                      -

          166,449

 Prepaid expenses

                    -   

                  -   

        384,164

  

          384,164

 Related party receivable

                    -   

          50,000

        451,077

                      -

         (501,077)

                    -   

 Subscription receivable

                    -   

                  -   

                  -   

                      -

 

                    -   

 Inventories

                    -   

                  -   

        487,470

                      -

                      -

          487,470

       

 Total current assets

                    -   

        250,442

     2,382,712

       5,184,630

         (501,077)

       7,316,707

       

 Property, plant and equipment

      

 Buildings

                    -   

                  -   

     1,575,401

  

       1,575,401

 Machinery and equipment

                    -   

                  -   

          42,236

  

            42,236

 Vehicles

                    -   

                  -   

          61,474

  

            61,474

 Computer equipment

                    -   

                  -   

            5,818

  

              5,818

 Office equipment

                    -   

                  -   

            3,512

  

              3,512

 Construction in progress

                    -   

                  -   

     1,030,199

                      -

                      -

       1,030,199

 Total

                    -   

                  -   

     2,718,640

                      -

                      -

       2,718,640

 Accumulated depreciation

                    -   

                  -   

       (131,391)

                      -

                      -

         (131,391)

 Net property, plant and equipment

                    -   

                  -   

     2,587,249

                      -

                      -

       2,587,249

       

 Investment in subsidiary

                    -   

        821,256

                  -   

                      -

         (821,256)

                    -   

 Prepaid land lease

                    -   

                  -   

          67,715

                      -

                      -

            67,715

Total other assets

                    -   

        821,256

          67,715

                      -

         (821,256)

            67,715

       

 Total assets

   $                 -                 

 $ 1,071,698

 $ 5,037,676

 $   5,184,630

 $(1,322,333)

 $   9,971,671

       

 Liabilities and stockholders' equity

      

 Current liabilities

      

 Trade accounts payable

 $                 -   

 $               -   

 $      67,431

 $                 -

 $                  -

 $        67,431

 Related party payable

                    -   

        821,756

                  -   

                      -

         (501,077)

          320,679

 Other payables

                    -   

        200,000

          54,607

  

          254,607

 Accrued expenses

                    -   

                  -   

               668

  

                 668

 Deposits

                    -   

                  -   

            4,962

  

              4,962

 Short-term notes payable

                    -   

                  -   

        533,213

                      -

                      -

          533,213

       

 Total current liabilities

                    -   

     1,021,756

        660,881

                      -

         (501,077)

       1,181,560

       

 Stockholders' equity

      

 Common stock

                 359

          50,000

        821,256

                      -

         (865,470)

              6,145

 Additional paid in capital

                (359)

                  -   

                  -   

       5,184,630

            44,214

       5,228,485

 Retained earnings

                    -   

                (58)

     3,555,539

                      -

                      -

       3,555,481

       

 Total stockholders' equity

                    -   

          49,942

     4,376,795

       5,184,630

         (821,256)

       8,790,111

       

 Total Liabilities and stockholders' equity

 $                 -   

 $ 1,071,698

 $ 5,037,676

 $   5,184,630

 $(1,322,333)

 $   9,971,671

1

See notes to unaudited pro-forma consolidated financial statements


MEDITECH PHARMACEUTICALS INC.


PRO-FORMA STATEMENTS OF OPERATIONS (UNAUDITED)


FOR THE YEAR ENDED DECEMBER 31, 2004




      
  

 BVI

 Bazhou

 Consolidating

 Pro-forma

 

 Meditech

 Deli Solar

 Deli Solar

 Entries

 Consolidated

      

Sales revenues

 $                 -   

 $                 -   

 $   9,380,246

 $                 -   

 $   9,380,246

Cost of goods sold

                    -   

                    -   

       6,633,836

                    -   

       6,633,836

      

Gross profit

                    -   

                    -   

       2,746,410

                    -   

       2,746,410

      

Operating expenses

     

Advertising

                    -   

                    -   

          249,084

                    -   

          249,084

Other selling expenses

                    -   

                    -   

            86,217

                    -   

            86,217

Salaries and benefits

                    -   

                    -   

          170,008

                    -   

          170,008

Depreciation

                    -   

                    -   

            31,471

                    -   

            31,471

Other general and administrative

          307,936

                    -   

          118,739

                    -   

          426,675

      

Total operating expenses

          307,936

                    -   

          655,519

                    -   

          963,455

      

Net operating income

         (307,936)

                    -   

       2,090,891

                    -   

       1,782,955

      

Other income (expense)

     

Interest income

                   70

                    -   

                    -   

                    -   

                   70

Interest expense

  

                  (43)

 

                  (43)

Gain on asset disposal

                    -   

                    -   

             (3,971)

                    -   

             (3,971)

Other

                    -   

                    -   

            50,148

                    -   

            50,148

      

Total other income (expense)

                   70

                    -   

            46,134

                    -   

            46,204

      

Net income before taxes

         (307,866)

                    -   

       2,137,025

                    -   

       1,829,159

      

Taxes

                    -   

                    -   

                    -   

                    -   

                    -   

      

Net income

 $   (307,866)

 $                 -   

 $   2,137,025

$                 -   

 $   1,829,159

    

Pre-split

Post-split

Basic EPS

   

 $            0.05

 $            0.30

Diluted EPS

   

 $            0.04

 $            0.23

      

Denominator for basic EPS

   

     36,850,589

       6,145,290

Denominator for diluted EPS

   

     48,164,903

       8,031,009





2

See notes to unaudited pro-forma consolidated financial statements


MEDITECH PHARMACEUTICALS INC.


PRO-FORMA STATEMENTS OF OPERATIONS (UNAUDITED)


FOR THE THREE MONTHS ENDED MARCH 31, 2005




      
  

 BVI

 Bazhou

 Consolidating

 Pro-forma

 

 Meditech

 Deli Solar

 Deli Solar

 Entries

 Consolidated

      

Sales revenues

 $                 -   

 $                 -   

 $   1,199,033

 $                 -   

 $   1,199,033

Cost of goods sold

                    -   

                    -   

          950,114

                    -   

          950,114

      

Gross profit

                    -   

                    -   

          248,919

                    -   

          248,919

      

Operating expenses

     

Advertising

                    -   

                    -   

            60,067

                    -   

            60,067

Other selling expenses

                    -   

                    -   

              6,704

                    -   

              6,704

Salaries and benefits

                    -   

                    -   

            28,966

                    -   

            28,966

Depreciation

                    -   

                    -   

              7,221

                    -   

              7,221

Other general and administrative

            44,041

                   58

            28,509

                    -   

            72,608

      

Total operating expenses

            44,041

                   58

          131,467

                    -   

          175,566

      

Net operating income

           (44,041)

                  (58)

          117,452

                    -   

            73,353

      

Other income (expense)

     

Interest income

                   23

                    -   

                    -   

                    -   

                   23

Interest expense

  

           (10,857)

 

           (10,857)

Gain on debt forgiveness

       2,278,158

                    -   

                    -   

      (2,278,158)

                    -   

      

Total other income (expense)

       2,278,181

                    -   

           (10,857)

      (2,278,158)

           (10,834)

      

Net income before taxes

       2,234,140

                  (58)

          106,595

      (2,278,158)

            62,519

      

Taxes

                    -   

                    -   

                    -   

                    -   

                    -   

      

Net income

 $   2,234,140

 $            (58)

 $      106,595

 $(2,278,158)

 $        62,519

    

Pre-split

Post-split

Basic EPS

   

 $                 -   

 $            0.01

Diluted EPS

   

 $                 -   

 $            0.01

      

Denominator for basic EPS

   

     36,850,589

       6,145,290

Denominator for diluted EPS

   

     48,164,903

       8,031,009



3

See notes to unaudited pro-forma consolidated financial statements


MEDITECH PHARMACEUTICALS INC.


NOTES TO UNAUDITED PRO-FORMA CONSOLIDATED FINANCIAL STATEMENTS


MARCH 31, 2005



1.

BASIS OF PRESENTATION


The unaudited pro-forma consolidated financial statements include the accounts of Meditech Pharmaceuticals, Inc. (Meditech), Deli Solar Holding Ltd. (BVI Deli Solar), and Bazhou Deli Solar Energy Heating Co., Ltd. (Bazhou Deli Solar). Meditech acquired 100% of the outstanding stock of BVI Deli Solar in a stock exchange on March 31, 2005 by issuing 24,407,784 shares of common stock (4,067,964 post-split). The transaction was accounted for as a recapitalization of BVI Deli Solar with the capital structure of Meditech. Prior to that, BVI Deli Solar acquired Bazhou Deli Solar in a transfer of entities under common control, wherein the prior owners of Bazhou Deli Solar incorporated BVI Deli Solar by investing registered capital of $50,000 and then transferring their ownership in Bazhou Deli Solar to BVI Deli Solar in exchange for promissory notes. In a transfer of entities under common control the transaction is presented as if it had occurred at the beginning of the first period presented. Thus, the resultant financial statements will be primarily those of BVI Deli Solar combined with Bazhou Deli Solar, adopting the capital structure of Meditech.


Meditech is the registrant, a Nevada company incorporated on March 21, 1983. Meditech has a fiscal year end of May 31. The balance sheet of Meditech on February 28, 2005, as filed with Form 10-QSB, contained no assets and no liabilities. The balance sheet of Meditech as of February 28, 2005 is presented in the pro-forma consolidated balance sheet. The statement of operations of Meditech for the year ended May 31, 2004, as filed with Form 10-KSB is presented in the pro-forma consolidated statement of operations for the year ended December 31, 2004. The statement of operations of Meditech for the three months ended February 28, 2005, as filed with Form 10-QSB is presented in the pro-forma consolidated statement of operations for the three months ended March 31, 2005. During the three months ended February 28, 2005, Meditech had no operations other than general and administrative expenses. The income from debt forgiveness will be non-recurring, and has therefore been eliminated on pro-forma consolidation.


BVI Deli Solar was incorporated in the British Virgin Islands on June 10, 2004, for the purpose of acquiring and holding Bazhou Deli Solar, and has no other operations. The unaudited balance sheet of BVI Deli Solar as of March 31, 2005 is included in the pro-forma consolidated balance sheet. BVI Deli Solar had no revenues or expenses for the period from inception to December 31, 2004. BVI Deli Solar had no revenues and only minimal expenses for the three months ended March 31, 2005. Accordingly, those expenses are included on the pro-forma consolidated statement of operations for the three months ended March 31, 2005.



4



MEDITECH PHARMACEUTICALS INC.


NOTES TO UNAUDITED PRO-FORMA CONSOLIDATED FINANCIAL STATEMENTS


MARCH 31, 2005



1.

BASIS OF PRESENTATION (Continued)


Bazhou Deli Solar was incorporated on August 19, 1997 in the People’s Republic of China (the PRC), and is in the business of manufacturing and selling solar energy heaters, heating stoves, related accessories, and other solar energy products within the PRC. Bazhou Deli Solar’s audited balance sheet as of December 31, 2004 is included in the pro-forma consolidated balance sheet. Bazhou Deli Solar’s audited statement of operations for the year ended December 31, 2004 is included in the pro-forma consolidated statement of operations for the year ended December 31, 2004, and its unaudited statement of operations for the three months ended March 31, 2005 is included in the pro-forma consolidated statement of operations for the three months ended March 31, 2005.


2.

CONSOLIDATING ENTRIES


The consolidating entries on the pro-forma consolidated balance sheet eliminate related party receivables against corresponding related party payables. There are also entries to eliminate investments in subsidiary accounts, to agree common stock to the post-acquisition common shares outstanding multiplied by par value, with adjustments being made against additional paid in capital accounts.


The consolidating entries on the pro-forma consolidated statement of operations for the three months ended March 31, 2005 eliminate the effect of a non-recurring gain on debt forgiveness.


3.

PRIVATE PLACEMENT


In conjunction with the acquisition transaction, the Company consummated a private placement wherein it issued 10,285,740 shares of common stock (1,714,290 post-split) and 5 year warrants to purchase an additional 10,285,740 (1,714,290 post-split) common shares at an exercise price of $0.64167 per share ($3.85 post-split) for gross proceeds of $6,000,015 less costs of issuance of $815,385. In connection with the private placement the Company issued 1,028,574 (171,429 post-split) 5 year warrants to financial advisors, making outstanding warrants for a total of 11,314,314 common shares (1,885,719 post-split).


4.

SUBSEQUENT REVERSE STOCK SPLIT


Subsequent to the acquisition the Company effected a 1:6 reverse stock split. The effects of the reverse split have been applied to the pro forma balance sheet.



5



MEDITECH PHARMACEUTICALS INC.


NOTES TO UNAUDITED PRO-FORMA CONSOLIDATED FINANCIAL STATEMENTS


MARCH 31, 2005



5.

EARNINGS PER SHARE


A reconciliation of the numerators and denominators used in calculating pre-split and post-split basic and diluted earnings per share is contained in the following table.


 

Pre-split

Post-split

 

2005

2004

2005

2004

NUMERATOR FOR BASIC AND DILUTED EPS

    

    Net income to common stockholders

 $         62,519

 $    1,829,159

 $         62,519

 $    1,829,159

     

DENOMINATORS FOR BASIC AND DILUTED EPS

    

Common stock outstanding at recapitalization

         25,836,797

         25,836,797

           4,309,658

           4,309,658

Add: Common stock issued in private placement

         11,013,792

         11,013,792

           1,835,632

           1,835,632

DENOMINATOR FOR BASIC EPS

         36,850,589

         36,850,589

           6,145,290

           6,145,290

Add: Outstanding stock warrants

         11,314,314

         11,314,314

           1,885,719

           1,885,719

DENOMINATOR FOR DILUTED EPS

         48,164,903

         48,164,903

           8,031,009

           8,031,009

     

EPS - Basic

 $                  -

 $             0.05

 $             0.01

 $             0.30

EPS - Diluted

 $                  -

 $             0.04

 $             0.01

 $             0.23




6